Switch theme
Sign up to access all valuation multiples
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
1999
68.6K+
LTM Revenue $42.7B
LTM EBITDA $14.7B
$98.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GSK has a last 12-month revenue (LTM) of $42.7B and a last 12-month EBITDA of $14.7B.
In the most recent fiscal year, GSK achieved revenue of $42.1B and an EBITDA of $9.0B.
GSK expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GSK valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $42.7B | XXX | $42.1B | XXX | XXX | XXX |
| Gross Profit | $31.8B | XXX | $30.0B | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $14.7B | XXX | $9.0B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 21% | XXX | XXX | XXX |
| EBIT | $12.4B | XXX | $7.4B | XXX | XXX | XXX |
| EBIT Margin | 29% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $8.9B | XXX | $3.5B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GSK's stock price is GBP 15 (or $20).
GSK has current market cap of GBP 59.0B (or $79.3B), and EV of GBP 73.0B (or $98.0B).
See GSK trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $98.0B | $79.3B | XXX | XXX | XXX | XXX | $2.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GSK has market cap of $79.3B and EV of $98.0B.
GSK's trades at 2.3x EV/Revenue multiple, and 10.9x EV/EBITDA.
Equity research analysts estimate GSK's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GSK has a P/E ratio of 8.9x.
See valuation multiples for GSK and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $79.3B | XXX | $79.3B | XXX | XXX | XXX |
| EV (current) | $98.0B | XXX | $98.0B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBIT | 7.9x | XXX | 13.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 8.9x | XXX | 22.9x | XXX | XXX | XXX |
| EV/FCF | 18.5x | XXX | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGSK's last 12 month revenue growth is 4%
GSK's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
GSK's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GSK's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GSK and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK acquired XXX companies to date.
Last acquisition by GSK was XXXXXXXX, XXXXX XXXXX XXXXXX . GSK acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GSK founded? | GSK was founded in 1999. |
| Where is GSK headquartered? | GSK is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does GSK have? | As of today, GSK has 68.6K+ employees. |
| Who is the CEO of GSK? | GSK's CEO is Dame Emma N. Walmsley. |
| Is GSK publicy listed? | Yes, GSK is a public company listed on LON. |
| What is the stock symbol of GSK? | GSK trades under GSK ticker. |
| When did GSK go public? | GSK went public in 1972. |
| Who are competitors of GSK? | Similar companies to GSK include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GSK? | GSK's current market cap is $79.3B |
| What is the current revenue of GSK? | GSK's last 12 months revenue is $42.7B. |
| What is the current revenue growth of GSK? | GSK revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of GSK? | Current revenue multiple of GSK is 2.3x. |
| Is GSK profitable? | Yes, GSK is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GSK? | GSK's last 12 months EBITDA is $14.7B. |
| What is GSK's EBITDA margin? | GSK's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of GSK? | Current EBITDA multiple of GSK is 6.7x. |
| What is the current FCF of GSK? | GSK's last 12 months FCF is $5.3B. |
| What is GSK's FCF margin? | GSK's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of GSK? | Current FCF multiple of GSK is 18.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
